脂肪肉瘤的临床病理和基因改变的研究进展

doi:10.11904/j.issn.1002-3070.2023.01.015

Abstract

Abstract: Liposarcoma is a malignant tumor originating from primitive mesenchymal cells,which has remarkable tissue diversity and consists of cells with different degrees of differentiation and atypia.Liposarcoma is mainly divided into four subtypes:atypical lipogenic tumors(ALT)with MDM2-HMGA2 as the key gene/well-differentiated liposarcoma(WDLPS)and dedifferentiated liposarcoma(DDLPS),myxoid liposarcoma(MLPS)/round cell liposarcoma(RCLPS)with FUS-CHOP gene fusion as the main mechanism,and pleomorphic liposarcoma(PLPS)with complex and variable pathogenesis.The main pathological changes of ALT/WDLPS are the proliferation of pleomorphic mature adipocytes,DDLPS is high-grade sarcoma,MLPS/RCLPS is mainly composed of non-lipid stromal cells,and PLPS is characterized by atypical multivacuolar adipocytes.The tumor gene and clinicopathological changes contained in these four subtypes lead to the different clinical behaviors,treatment sensitivity and biological characteristics of these four subtypes.This paper summarizes and discusses the pathological and genetic changes of these four subtypes.

Key words: Liposarcoma, Pathology, Immunohistochemistry

CLC Number:

R738.6

LI Saiyang, BAO Junjie, QU Guofan. Research progress on clinicopathological and genetic alterations of liposarcoma[J]. Journal of Practical Oncology, 2023, 37(1): 83-86.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.01.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I1/83

References

1 Lee ATJ,Thway K,Huang PH,et al.Clinical and molecular spectrum of liposarcoma[J].J Clin Oncol,2018,36(2):151-159.
2 Ray-coquard I,Serre D,Reichardt P,et al.Options for treating different soft tissue sarcoma subtypes[J].Future Oncol,2018,14(10):25-49.
3 Thway K.Well-differentiated liposarcoma and dedifferentiated liposarcoma:an updated review[J].Semin Diagn Pathol,2019,36(2):112-121.
4 Mashima E,Sawada Y,Nakamura M.Recent advancement in atypical lipomatous tumor research[J].Int J Mol Sci,2021,22(3):994.
5 Wang GY,Lucas DR.Dedifferentiated liposarcoma with myofibroblastic differentiation[J].Arch Pathol Lab Med,2018,142(10):1159-1163.
6 Kilpatrick SE.Dedifferentiated liposarcoma:a comprehensive historical review with proposed evidence-based guidelines regarding a diagnosis in need of further clarification[J].Adv Anat Pathol,2021,28(6):426-438.
7 Baranov E,Black MA,Fletcher CDM,et al.Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas[J].Mod Pathol,2021,34(7):1367-1372.
8 Mujtaba B,Wang F,Taher A,et al.Myxoid liposarcoma with skeletal metastases:pathophysiology and imaging characteristics[J].Curr Probl Diagn Radiol,2021,50(1):66-73.
9 Abaricia S,Hirbe AC.Diagnosis and treatment of myxoid liposarcomas:Histology matters[J].Curr Treat Options Oncol,2018,19(12):64.
10 Tfayli Y,Baydoun A,Naja AS,et al.Management of myxoid liposarcoma of the extremity[J].Oncol Lett,2021,22(2):596.
11 Nautiyal H,Egiz A,Farajzadeh Asl S,et al.Epithelioid variant of pleomorphic liposarcoma:a rare challenging diagnosis causing severe medial thigh pain[J].Cureus,2021,13(11):e19531.
12 Gjorgova Gjeorgjievski S,Thway K,Dermawan JK,et al.Pleomorphic liposarcoma:a series of 120 cases with emphasis on morphologic variants[J].Am J Surg Pathol,2022,46(12):1700-1705.
13 Anderson WJ,JO VY.Pleomorphic liposarcoma:updates and current differential diagnosis[J].Semin Diagn Pathol,2019,36(2):122-128.
14 Sciot R.MDM2 amplified sarcomas:a literature review[J].Diagnostics(Basel),2021,11(3):496.
15 Yang L,Chen S,Luo P,et al.Liposarcoma:advances in cellular and molecular genetics alterations and corresponding clinical treatment[J].J Cancer,2020,11(1):100-107.
16 Kuusk A,Boyd H,Chen H,et al.Small-molecule modulation of p53 protein-protein interactions[J].Biol Chem,2020,401(8):921-931.
17 Serra S,Chetty R.p16[J].J Clin Pathol,2018,71(10):853-858.
18 Lu J,Wood D,Ingley E,et al.Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma[J].Mol Biol Rep,2021,48(4):3637-3647.
19 Wu H,Li X,Shen C.Peroxisome proliferator-activated receptor gamma in white and brown adipocyte regulation and differentiation[J].Physiol Res,2020,69(5):759-773.
20 Thway K,Fisher C.Undifferentiated and dedifferentiated soft tissue neoplasms:immunohistochemical surrogates for differential diagnosis[J].Semin Diagn Pathol,2021,38(6):170-186.
21 Kanojia D,Nagata Y,Garg M,et al.Genomic landscape of liposarcoma[J].Oncotarget,2015,6(40):42429-42444.
22 Owen I,Yee D,Wyne H,et al.The oncogenic transcription factor FUS-CHOP can undergo nuclear liquid-liquid phase separation[J].J Cell Sci,2021,134(17):jcs258578.
23 Scapa JV,Cloutier JM,Raghavan SS,et al.DDIT3 immunohistochemistry is a useful tool for the diagnosis of myxoid liposarcoma[J].Am J Surg Pathol,2021,45(2):230-239.
24 Demetri GD,Antonescu CR,Bjerkehagen B,et al.Diagnosis and management of tropomyosin receptor kinase(TRK)fusion sarcomas:expert recommendations from the World Sarcoma Network[J].Ann Oncol,2020,31(11):1506-1517.
25 Berthold R,Isfort I,Erkut C,et al.Fusion protein-driven IGF-IR/PI3K/Akt signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma[J].Oncogenesis,2022,11(1):20.
26 Compton ML,AL-rohil RN.The utility of perilipin in liposarcomas:PLIN1 differentiates round cell liposarcoma from other round cell sarcomas[J].Appl Immunohistochem Mol Morphol,2021,29(2):152-157.
27 Pollack SM.The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients[J].Expert Rev Vaccines,2018,17(2):107-114.
28 Creytens D.What′s new in adipocytic neoplasia?[J].Virchows Arch,2020,476(1):29-39.
29 Creytens D,Folpe AL,Koelsche C,et al.Myxoid pleomorphic liposarcoma-a clinicopathologic,immunohistochemical,molecular genetic and epigenetic study of 12 cases,suggesting a possible relationship with conventional pleomorphic liposarcoma[J].Mod Pathol,2021,34(11):2043-2049.
30 Peng R,Li N,Lan T,et al.Liposarcoma in children and young adults:a clinicopathologic and molecular study of 23 cases in one of the largest institutions of China[J].Virchows Arch,2021,479(3):537-549.
31 Tiemeier GL,Brown JM,Pratap SE,et al.Pleomorphic liposarcoma of bone:a rare primary malignant bone tumour[J].Clin Sarcoma Res,2018,8:2.

[1]	SUN Weiling, ZHANG Minghui, WU Huaxing, ZHAO Yanbin. Predictive value of serum tumor markers in histopathological types of bronchoscopy biopsy in patients with lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 316-322.
[2]	ZHAO Baoshan, LIANG Guanying, XU Shengjie, QIAO Hui, CHEN Hongxia, MA Ying, JU Xueping, WANG Lin. Analysis of the correlation between PELP1 expression and gastric cancer progression and prognosis [J]. Journal of Practical Oncology, 2022, 36(1): 31-36.
[3]	WANG Yuping, SI Meili, SUN Xiaoxia, GUO Yulin. High expression of HPIP in endometrial carcinoma and its significance in the analysis of survival and prognosis [J]. Journal of Practical Oncology, 2022, 36(1): 44-48.
[4]	WANG Lina, WANG Le, JIN Hong, LI Qi, CHENG Haiyan. The expression of UBQLN1 in cervical cancer and its effect on prognosis [J]. Journal of Practical Oncology, 2021, 35(6): 506-510.
[5]	WANG Zhe, ZHU Shuai, LIU Huan, FU Qiang, HU Tenglong. Expression,correlation and clinical significance of SRPX2 and Rab31 in oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 414-419.
[6]	LU Junrong, WANG Huiwen, HE Dongfeng. Significance of high expression of SALL4 in clinicopathological and prognostic judgment of esophageal squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 420-425.
[7]	ZHANG Lianqi,LI Jichen,PIAO Songlin,SAI Yin wuliji,YUAN Dongmei,SHEN Yuchen. Expression and clinical significance of PD-L1 and MTA1 in the oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2020, 34(3): 220-224.
[8]	XU Ting, YAN Feifei, ZHANG Chunhui, ZHANG Yanqiao. Analysis of clinical pathology and prognosis in patients with gastric cancer & bone metastasis [J]. Journal of Practical Oncology, 2019, 33(5): 436-441.
[9]	WANG Jinyou, HE Ke, XIE Dongdong, BI Liangkuan, XU Dexiang, YU Dexin. Expression and significance of FBXW10 and cyclin E in renal clear cell carcinoma [J]. Journal of Practical Oncology, 2019, 33(4): 323-327.
[10]	LI Jiaqi,LUAN Jinwei,ZHANG Yu,LI Xianglan. Analysis of clinicopathological features,recurrence and metastasis in 763 triple-negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 244-249.
[11]	XING Zhichao, MAI Wei. Research progress on potential targets of liposarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 82-86.
[12]	HE Xu, YE shangmian, DONG dandan, LI Ke. The expression of HLA-G in breast cancer and its significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 410-414.
[13]	FANG Zhenjian,WU Zhengcong,ZHENG Hongzong,AO Riying,LAI Guoxiang. Diagnostic value of CT enhancement for solitary pulmonary nodules of different size [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 333-336.
[14]	WANG Jiana, SHEN Jianjun, ZHANG Yanhong, WANG Jiatian, LI Wenxiu, PAN Junying. Expression of Ki-67 and PTEN in oral adenoid cystic carcinoma and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 489-493.
[15]	ZHANG Chunhui, LIU Xia, XU Jingjing, ZHOU Yanhua, ZHAO Juan, LI Zhiwei, ZHANG Yanqiao. Clinicopathological features and survival analysis in 633 cases of gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 396-404.

Research progress on clinicopathological and genetic alterations of liposarcoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments